Kairos Pharma Ltd. (NYSE American: KAPA) announced that CEO and Chairman Dr. John Yu will present at the 16th Annual LD Micro Invitational on May 18, 2026, at 1:00 p.m. PDT at the Luxe Sunset Boulevard Hotel in Los Angeles. During the presentation, Dr. Yu will provide an update on the company’s clinical program and partnering activities.
The presentation comes as Kairos Pharma advances its lead candidate, ENV-105, an antibody targeting CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs.
For the investment community, this presentation offers a crucial opportunity to gauge the company’s progress in oncology therapeutics. The LD Micro Invitational is a well-known event that connects emerging growth companies with investors, and Kairos Pharma’s participation signals its commitment to transparency and advancing its pipeline. The company’s focus on overcoming drug resistance and immune suppression in cancer could have substantial implications for patients and the broader oncology market.
Kairos Pharma, based in Los Angeles, California, utilizes structural biology to develop therapies that address cancer resistance mechanisms. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. However, the ongoing clinical trials represent a significant step toward potential new treatment options.
For more details, the full press release is available at https://ibn.fm/g3aQY. The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA.
